Systematic review of genetic influences on the prognosis of colorectal cancer

British Journal of Surgery

Volumn 91, Issue 10, 2004, Pages 1275-1291

  Anwar, S ^a   Frayling, I M ^b   Scott, N A ^a   Carlson, G L ^a  

^a HOPE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENETICS; CANCER STATISTICS; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COCHRANE LIBRARY; COLORECTAL CANCER; DCC GENE; EMBASE; FOLLOW UP; GENE; GENE LOCUS; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENOME; HEREDITY; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; MEDLINE; META ANALYSIS; NM23 GENE; ONCOGENE K RAS; PATHOGENESIS; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEQUENCE ANALYSIS; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE;

BASE PAIR MISMATCH; COLORECTAL NEOPLASMS; EVIDENCE-BASED MEDICINE; GENES, P53; GENES, RAS; HUMANS; MICROSATELLITE REPEATS; NUCLEOSIDE-DIPHOSPHATE KINASE; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 4944235005     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.4737     Document Type: Review

References (171)

1. Marshall JB. Colorectal cancer screening: present strategies and future prospects. Postgrad Med 1996; 99: 253-266.
2. Toribara NW, Sleisenger MH. Screening for colorectal cancer. N Engl J Med 1995; 332: 861-867.
3. Weinberg RA. Oncogenes, antioncogenes and the molecular bases of multistep carcinogenesis. Cancer Res 1989; 49: 3713-3721.
4. Bishop JM. The molecular genetics of cancer. Science 1987; 235: 305-311.
5. Fearon ER, Vogelstein B. A genetic model of colorectal tumorigenesis. Cell 1990; 61: 759-767.
6. Vogelstein B, Fearon ER, Hamilton SR, Kam SE, Preisinger AC, Leppert M et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532.
7. Vogelstein B, Fearon ER, Kerr SE, Hamilton SR, Presinger AC, Nakamura Y et al. Allelotype of colorectal cancer. Science 1989; 244: 207-211.
8. Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, Vogelstein B et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994; 54: 5523-5526.
9. Hao XP, Frayling IM, Sgouros LG, Du MQ, Willcocks TC, Talbot IC et al. The spectrum of p53 mutations in colorectal adenomas differs from that in colorectal carcinomas. Gut 2002; 50: 834-839.
10. Carethers JM. The cellular and molecular pathogenesis of colorectal cancer. Gastroenterol Clin N Am 1996; 25: 737-754.
11. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988; 80: 200-204.
12. Georgiades IB, Curtis LJ, Morris RM, Bird CC, Wyllie AH. Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability. Oncogene 1999; 18: 7933-7940.
13. Pallai R. Oncogenes and oncoproteins as tumor markers. Eur J Surg Oncol 1992; 18: 417-424.
14. Der CJ, Krontiris TA, Cooper GM. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci USA 1982; 79: 3637-3640.
15. Shimizu K, Goldfarb M, Perucho M, Wigler M. Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line. Proc Natl Acad Sci USA 1983; 80: 383-387.
16. Meltzer SJ, Ahnen DJ, Battifora H, Yokota J, Cline MJ. Protooncogene abnormalities in colon cancers and adenomatous polyps. Gastroenterology 1987; 92: 1174-1180.
17. Cartwright CA, Kamps MP, Meisler AI, Pipas JM, Eckhart W. pp60 c-src activation in human colon carcinoma. J Clin Invest 1989; 83: 2025-2033.
18. Barbacid M. ras genes. Annu Rev Biochem 1987; 56: 779-827.
19. Benhatter J, Losi L, Chaubert P, Givel JC, Costa J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1993; 104: 1044-1048.
20. Lee JC, Wang ST, Lai MD, Lin YJ, Yang HB. K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. Anticancer Res 1996; 16: 3839-3844.
21. Thebo JS, Senagore AJ, Reinhold DS, Stapleton SR. Molecular staging of colorectal cancer: K-ras mutation analysis of lymph nodes upstages Dukes B patients. Dis Colon Rectum 2000; 43: 155-159.
22. Finkelstein SD, Sayegh R, Bakker A, Swalsky P. Determination of tumor aggressiveness in colorectal carcinoma by K-ras 2 analysis. Arch Surg 1993; 128: 526-532.
23. Moerkerk P, Arends JW, van Driel M, de Bruine A, de Goeij A, ten Kate J. Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res 1994; 54: 3376-3378.
24. Pajkos G, Kiss I, Sandor J, Ember I, Kishazi. The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. Anticancer Res 2000; 20: 1695-1701.
25. Suchy B, Zietz C, Rabes HM. K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis. Int J Cancer 1992; 52: 30-33.
26. Halter SA, Webb L, Rose J. Lack of ras mutations and prediction of long-term survival in carcinoma of the colon. Mod Pathol 1992; 5: 131-134.
27. Oudejans JJ, Slebos RJ, Zoetmulder FA, Mooi WJ, Rodenhuis S. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer 1991; 49: 875-879.
28. Tanaka M, Omura K, Watanabe Y, Oda Y, Nakanishi I. Prognostic factors of colorectal cancer: K-ras mutation, overexpression of p53 protein, and cell proliferative activity. J Surg Oncol 1994; 57: 57-64.
29. Belly RT, Rosenblatt JD, Steinmann M, Toner J, Sun J, Shehadi J et al. Detection of mutated K12-ras in histologically negative lymph nodes as an indicator of poor prognosis in stage II colorectal cancer. Clin Colorectal Cancer 2001; 1: 110-116.
30. Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002; 13: 1438-1446.
31. Lee JC, Wang ST, Lai MD, Lin YJ, Yang HB. K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. Anticancer Res 1996; 16: 3839-3844.
32. Span M, Moerkerk PT, De Goeij AF, Arends JW. A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer 1996; 69: 241-245.
33. Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 15: 299-304.
34. Cerottini JP, Caplin S, Saraga E, Givel JC, Benhattar J. The type of K-ras mutation determines prognosis in colorectal cancer. Am J Surg 1998; 175: 198-202.
35. Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA Jr et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998; 58: 1149-1158.
36. Senagore AJ, Biener JT. A newly identified pattern of K-ras mutations at codons 12 and 13 is associated with long-term survival in colorectal cancer. Surgery 1997; 122: 765-770.
37. Laurent-Puig P, Olschwang S, Delattre O, Remvikos Y, Asselain B, Melot T et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992; 102: 1136-1141.
38. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GE et al. Prognostic value of p53 overexpression and c-Ki-ras mutations in colorectal cancer. Gastroenterology 1993; 104: 57-64.
39. Markowitz S, Hines JD, Lutterbaugh J, Myeroff L, Mackay W, Gordon N et al. Mutant K-ras oncogenes in colon cancers do not predict patients chemotherapy response or survival. Clin Cancer Res 1995; 1: 441-445.
40. Andreyev HJN, Tilsed JVT, Cunnigham D, Sampson SA, Norman AR, Schneider HJ et al. K-ras mutations in patients with early colorectal cancer. Gut 1997; 41: 323-329.
41. Dix BR, Robbins P, Soong R, Jenner D, House AK, Iacopetta BJ. The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 1994; 59: 747-751.
42. Bouzourene H, Gervaz P, Cerottini JP, Benhattar J, Chaubert P, Saraga E et al. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 2000; 36: 1008-1015.
43. Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Hermans J, Buys CC et al. Impact of K-ras and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer. Am J Gastroenterol 2000; 95: 2953-2957.
44. Morrin M, Kelly M, Barrett N, Delaney P. Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. Gut 1994; 35: 1627-1631.
45. Clarke GA, Ryan E, Crowe JP, O'Keane JC, MacMathuna P. Tumour-derived mutated K-ras codon 12 expression in regional lymph nodes of stage II colorectal cancer patients is not associated with increased risk of cancer-related death. Int J Colorectal Dis 2001; 16: 108-111.
46. Andersen SN, Lovig T, Breivik J, Lund E, Gaudernack G, Meling GI et al. K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol 1997; 32: 62-69.
47. Hirvikoski P, Auvinen A, Servomaa K, Kiuru A, Rytomaa T, Makonen K et al. K-ras and p53 mutations and overexpresion as prognostic factors in female rectal carcinoma. Anticancer Res 1999; 19: 685-691.
48. Pricola VE, Finkelstein SD, Wu TT, Keller G, Bakker A, Swalsky PA et al. Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am J Surg 1996; 171: 41-46.
49. Kastrinakis WV, Ramchurren N, Maggard M, Steele G Jr, Summerhayes IC. K-ras status does not predict successful hepatic resection of colorectal cancer metastasis. Arch Surg 1995; 130: 9-14.
50. Kern SE, Fearon ER, Tersmette KW, Enterline JP, Leppert M, Nakamura Y et al. Clinical and pathological associations with allelic losses in colorectal carcinoma. JAMA 1989; 261: 3099-3103.
51. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, deary K et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-708.
52. Yamaguchi A, Kurosaka Y, Fushida S, Kanno M, Yonemura Y, Miwa K et al. Expresion of p53 protein in colorectal cancer and its relationship to short term prognosis. Cancer 1992; 70: 2778-2784.
53. Hemelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y et al. Association of p53 mutation with short survival in colorectal cancer. Gastroenterology 1994; 106: 42-48.
54. Remvikos Y, Tominaga O, Hammel P, Laurent Puig P, Salmon RJ, Dutrillaux B et al. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 1992; 66: 758-764.
55. Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992; 66: 558-562.
56. Sun XF, Carstensen JM, Stal O, Zhang H, Nilsson E, Sjodahl R et al. Prognostic significance of p53 expression in relation to DNA ploidy in colorectal adenocarcinoma. Virchows Arch A Pathol Anat Histopathol 1993; 423: 443-448.
57. Sun XF, Carstensen JM, Zhang H, Stal O, Wingren S, Hatschek T et al. Prognostic significance of cytoplasmic p52 oncoprotein in colorectal adenocarcinoma. Lancet 1992; 340: 1369-1373.
58. Auvinen A, Isola J, Visakorpi T, Koivula T, Virtanen S, Hakama M. Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 1994; 70: 293-296.
59. Laing JT, Cheng YM, Chang KJ, Chien CT, Hsu HC. Reappraisal of K-ras and p53 gene mutations in the recurrence of Dukes' B2 rectal cancer after curative resection. Hepatogastroenterology 1999; 46: 830-837.
60. Slebos RJC, Bass IO, Clement M, Polak M, Mulder JW, van den Berg FM et al. Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21 WAF/Cip1 in colorectal carcinoma. Br J Cancer 1996; 74: 165-171.
61. Buglioni S, D'Agnano I, Cosimelli M, Vasselli S, D'Angelo C, Tedesco M et al. Evaluation of multiple bio-pathologiocal factors in colorectal adenocarcinoma: independent prognostic role of p53 and bcl-2. Int J Cancer 1999; 22: 545-552.
62. Zeng ZS, Sarkis AS, Zhang ZF, Klimstra DS, Charytonowicz E, Guillem JG et al. p53 nuclear overexpression: an independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 1999; 12: 2043-2050.
63. Zhang H. Evaluation of four antibodies in detecting p53 protein for predicting clinicopathological and prognostic significance in colorectal adenocarcinoma. Clin Cancer Res 1999; 5: 4126-4132.
64. Smith DR, Ji CY, Goh HS. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 1996; 74: 216-223.
65. Kawasaki Y, Monden T, Morimoto H, Murotani M, Miyoshi Y, Kobayashi T et al. Immunohistochemical study of p53 expression in microwave-fixed paraffin-embedded sections of colorectal carcinoma and adenoma. Am J Clin Pathol 1992; 97: 244-249.
66. Goh HS, Elnatan J, Low CH, Smith DR. p53 mutation and survival in colorectal cancer patients: effect of disease dissemination and tumour location. Int J Oncol 1999; 15: 491-498.
67. Offerhaus GJ, De Feytar EP, Cornelisse CJ, Tersmette KW, Floyd J, Kern SE et al. The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology 1992; 102: 1612-1619.
68. Tortola S, Marcuello E, Gonzalez I, Reyes G, Arribas R, Aiza G et al. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 1999; 17: 1375-1381.
69. Schwandner O, Bruch HP, Broll R. p21, p27, cyclin D1, and p53 in rectal cancer: immunohistology with prognostic significance? Int J Colorectal Dis 2002; 17: 11-19.
70. Rebischung C, Gerard JP, Gayet J, Thomas G, Hamelin R, Laurent-Pugh P. Prognostic value of p53 mutations in rectal carcinoma. Int J Cancer 2002; 100: 131-135.
71. Okubo R, Masuda H, Nemoto N. p53 mutation found to be a significant prognostic indicator in distal colorectal cancer. Oncol Rep 2001; 8: 509-514.
72. Kahlenberg MS, Stoler DL, Rodriguez-Bigas MA, Weber TK, Driscoll DL, Anderson GR et al. p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma. Cancer 2000; 88: 1814-1819.
73. Cascinu S, Graziano F, Catalane V, Staccioli MP, Rossi MC, Baldelli AM et al. An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation. Br J Cancer 2002; 86: 744-749.
74. Schelwies K, Sturm I, Grabowski P, Scherubl H, Schindler I, Hermann S et al. Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumours. Int J Cancer 2002; 99: 589-596.
75. Diez M, Medrano M, Maguerza JM, Ramos P, Hernandez P, Villeta R et al. Influence of tumor localization on the prognostic value of p53 protein in colorectal adenocarcinomas. Anticancer Res 2000; 20: 3907-3912.
76. Kressner U, Inganas M, Byding S, Blikstad I, Pahlman L, Glimelius B et al. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 1999; 17: 593-599.
77. Manne U, Weiss HL, Myers RB, Danner OK, Moron C, Srivastava S et al. Nuclear accumulation of p53 in colorectal adenocarcinoma: prognostic importance differs with race and location of the tumor. Cancer 1998; 83: 2456-2467.
78. Nitti D, Belluco C, Montesco MC, Bertorelle R, Da Pian PP, Fassina A et al. Nuclear p53 protein expression in resected hepatic metastasis from colorectal cancer: an independent prognostic factor of survival. Eur J Cancer 1998; 34 851-855.
79. Borresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 1998; 4: 203-210.
80. Pricolo VE, Finkelstein SD, Hansen K, Cole BF, Bland KI. Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma. Arch Surg 1997; 132: 371-374.
81. Manne U, Myers RB, Moron C, Poczatek RB, Dillard S, Weiss H et al. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 1997; 74: 346-358.
82. Soong R, Grieu F, Robbins P, Dix B, Chen D, Parsons R et al. p53 alterations are associated with improved prognosis in distal colonie carcinoma. Clin Cancer Res 1997; 3: 1405-1411.
83. Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS et al. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 2000; 36: 2053-2060.
84. Elsaleh H, Powell B, Soontrapornchai P, Joseph D, Goria F, Spry N et al. p53 gene mutation microsatellite instability and adjuvant chemotherapy: impact on survival of 388 pateints with Dukes' C colon carcinoma. Oncology 2000; 58: 52-59.
85. Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 1991; 63: 317-319.
86. Lanza G Jr, Maestri I, Dubini A, Gafa R, Santini A, Ferretti S et al. p53 expression in colorectal cancer: relation to tumor type, DNA ploidy pattern and short-term survival. Am J Clin Pathol 1996; 105: 604-612.
87. Bosari S, Viale G, Roncalli M, Graziani D, Borsani G, Lee AK et al. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 1995; 147: 790-798.
88. Mulder JW, Baas IO, Polak MM, Goodman SN, Offerhaus GJ. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 1995; 71: 1257-1262.
89. Campo E, Miquel R, Jares P, Bosch F, Jaun M, Leone A et al. Prognostic significance of the loss of heterozygosity of Nm23H-H1 and p53 genes in human colorectal carcinomas. Cancer 1994; 73: 2913-2921.
90. O'Connell MJ, Schaid DJ, Ganju V, Cunningham J, Kovach JS, Thibodeau SN. Current status of adjuvant chemotherapy for colorectal cancer. Can molecular markers play a role in predicting prognosis? Cancer 1992; 70: (Suppl): 1732-1739.
91. Pasz-Walczak G, Kordek R, Faflik M. P21 (WAF1) expression in colorectal cancer: correlation with p53 and cyclin D1 expression, clinicopathological parameters and prognosis. Pathol Res Pract 2001; 197: 683-689.
92. Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF et al. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 2002; 99: 597-602.
93. Saw RP, Koorey D, Painter D, Gallagher PJ, Solomon MJ. p53 DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer. Br J Surg 2002; 89: 1409-1415.
94. Bazan V, Migliavacca M, Zanna I, Tubiolo C, Corsale S, Calo V et al. DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study. J Cancer Res Clin Oncol 2002; 128: 650-658.
95. Gunther K, Dworak O, Remke S, Pfluger R, Merkel S, Hohenberger W et al. Prediction of distant metastases after curative surgery for rectal cancer. J Surg Res 2002; 103: 68-78.
96. Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P et al. Investigation of the prognostic and predictive value of thymidylate synthetase, p53 and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002; 20: 1735-1743.
97. Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, Gosh N et al. Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum 2001; 44: 523-533.
98. Gallego MG, Acenero MJ, Ortega S, Delgado AA, Cantero JL. Prognostic influence of p53 nuclear overexpression in colorectal carcinoma. Dis Colon Rectum 2000; 43: 971-975.
99. Elsaleh H, Soontrapornchai P, Grieu F, Joseph D, Iacopetta B. p53 alterations have no prognostic or predictive significance Dukes' C rectal carcinomas. Int J Oncol 1999; 15: 1239-1243.
100. Tollenaar RA, van Krieken JH, van Slooten HJ, Bruinvels DJ, Nelemans KM, van den Broek LJ et al. Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: no evidence for prognostic significance. Br J Cancer 1998; 77: 1842-1847.
101. Poller DN, Baxter KJ, Shepherd NA. p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer? Br J Cancer 1997; 75: 87-93.
102. Bhatavdekar JM, Patel DD, Ghosh N, Chikhlikar PR, Trivedi TI, Suthar TP et al. Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum 1997; 40: 785-790.
103. Muleris M, Salmon RJ, Zafrani B, Girodet J, Dutrillaux B. Consistent deficiencies of chromosome 18 and of the short arm of chromosome 17 in eleven cases of human large bowel cancer: a possible recessive determinism. Ann Genet 1985; 28: 206-213.
104. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM et al. Identification of a chromosome 18q gene that is altered in colorectal cancer. Science 1990; 247: 49-56.
105. Woodford-Richens KL, Rowan AJ, Gorman P, Halford S, Bicknell DC, Wasan HS et al. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway. Proc Natl Acad Sci USA 2001; 98: 9719-9723.
106. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994; 331: 213-221.
107. Jernvall P, Makinen MJ, Karttunen TJ, Makela J, Vihko P. Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J Cancer 1999; 79: 903-908.
108. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G Jr et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996; 335: 1727-1732.
109. Martinez-Lopez E, Abad A, Font A, Monzo M, Ojanguren I, Pifarre A et al. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 1998; 114: 1180-1187.
110. Iino H, Fukayama M, Maeda Y, Koike M, Mori T, Takahashi T et al. Molecular genetics for clinical management of colorectal carcinoma. 17p, 18q, and 22q loss of heterozygosity and decreased DCC expression are correlated with the metastatic potential. Cancer 1994; 73: 1324-1331.
111. Kataoka M, Okabayashi T, Orita K. Decreased expression of DCC mRNA in gastric and colorectal cancer. Surg Today 1995; 25: 1001-1007.
112. Kato M, Ito Y, Kobayashi S, Isono K Detection of DCC and Ki-ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence. Cancer 1996; 77(Suppl): 1729-1735.
113. Ookawa K, Sakamoto M, Hirohashi S, Yoshida Y, Sugimura T, Terada M et al. Concordant p53 and DCC alterations and allelic losses on chromosomes 13q and 14q associated with liver metastases of colorectal carcinoma. Int J Cancer 1993; 53: 382-387.
114. Zetter BR. Adhesion molecules in tumor metastasis. Semin Cancer Biol 1993; 4: 219-229.
115. Saito M, Yamaguchi A, Goi T, Tuchiyama T, Nakagawara G, Urano T et al. Expression of DCC protein in colorectal tumors and its relationship to tumor progression and metastasis. Oncology 1999; 56: 134-141.
116. Reymond MA, Dworak O, Remke S, Hohenberger W, Kirchner T, Kockerling F. DCC protein as a predictor of distant metastases after curative surgery for rectal cancer. Dis Colon Rectum 1998; 41: 755-760.
117. Sun XF, Rutten S, Zhang H, Nordenskjold B. Expression of the deleted in colorectal cancer gene is related to the prognosis in DNA diploid and low proliferative adenocarcinoma. J Clin Oncol 1999; 17: 1745-1750.
118. Lanza G, Matteuzzi M, Gafa R, Orvieto E, Maestri I, Santini A et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998; 79: 390-395.
119. Carethers JM, Hawn MT, Greenson JK, Hitchcock CL, Boland CR. Prognostic significance of allelic loss at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 1998; 114: 1188-1195.
120. Cohn KH, Ornstein DL, Wang F, LaPaix FD, Phipps K, Edelsberg C et al. The significance of allelic deletions and aneuploidy in colorectal carcinoma. Results of a 5-year follow-up study. Cancer 1997; 15: 233-244.
121. Martinez JA, Prevot S, Nordlinger B, Nguyen TMA, Lacarriere Y, Munier A et al. Overexpression of nm23-H1 and nm23-H2 genes in colorectal carcinomas and loss of nm23-H1 expression in advanced tumour stages. Gut 1995; 37: 712-720.
122. Ayhan A, Yasui W, Yokozaki H, Kitadai Y, Tahara E. Reduced expression of nm23 protein is associated with advanced tumor stage and distant metastases in human colorectal carcinomas. Virchows Archiv B Cell Pathol Incl Mol Pathol 1993; 63: 213-218.
123. Yamaguchi A, Urano T, Fushida S, Furukawa K, Nishimura G, Yonemura Y et al. Inverse association of nm23-H1 expression by colorectal cancer with liver metastasis. Br J Cancer 1993; 68: 1020-1024.
124. Cohn KH, Wang FS, De Soto LaPaix F, Solomon WB, Patterson LG, Arnold MR et al. Association of nm23-H1 allelic deletions with distant metastases in colorectal carcinoma. Lancet 1991; 338: 722-724.
125. Berney CR, Fisher RJ, Yang J, Russell PJ, Crowe PJ. Genomic alterations (LOH, MI) on chromosome 17q21-23 and prognosis of sporadic colorectal cancer. Int J Cancer 2000; 89: 1-7.
126. Royds JA, Cross SS, Silcocks PB, Scholefield JH, Rees RC, Stephenson TJ. Nm23 'anti-metastatic' gene product expression in colorectal carcinoma. J Pathol 1994; 172: 261-266.
127. Haut M, Steeg PS, Wilson JK, Markowitz SD. Induction of nm23 gene expression in human colonic neoplasms and equal expression in colon tumors of high and low metastatic potential. J Natl Cancer Inst 1991; 83: 712-716.
128. Myeroff LL, Markowitz SD. Increased nm23-H1 and nm23-H2 messenger RNA expression and absence of mutations in colon carcinomas of low and high metastatic potential. J Natl Cancer Inst 1993; 85: 147-152.
129. Heide I, Thiede C, Poppe K, de Kant E, Huhn D, Rochlitz C. Expression and mutational analysis of Nm23-H1 in liver metastases of colorectal cancer. Br J Cancer 1994; 70: 1267-1271.
130. Lamb RF, Going JJ, Pickford I, Birnie GD. Allelic imbalance at NME1 in microdissected primary and metastatic human colorectal carcinomas is frequent but not associated with metastasis to lymph nodes or liver. Cancer Res 1996; 56: 916-920.
131. Ichikawa W. Positive relationship between expression of CD44 and hepatic metastases in colorectal cancer. Pathobiology 1994; 62: 172-179.
132. Iacopetta B, DiGrandi S, Dix B, Haig C, Soong R, House A. Loss of heterozygosity of tumour suppressor gene loci in human colorectal carcinoma. Eur J Cancer 1994; 30A: 664-670.
133. Forte A, D'Urso A, Gallinaro LS, Lo Storto G, Soda G, Bosco D et al. NM23 expression as prognostic factor in colorectal carcinoma. G Chir 2002; 23: 61-63.
134. Lee JC, Lin YJ, Chow NH, Wang ST. Reappraisal of the role of NM23-H1 in colorectal cancer. J Surg Oncol 2001; 76: 58-62.
135. Tabuchi Y, Nakamura T, Kuniyasu T, Ohno M, Nakae S. Expression of m23-H1 in colorectal cancer: no association with metastases, histological stage, or survival. Surg Today 1999; 29: 116-120.
136. Heys SD, Langlois N, Smith IC, Walker LG, Eremin O. NM23 gene product expression does not predict lymph node metastases or survival in young patients with colorectal cancer. Oncol Rep 1998; 5: 735-739.
137. Peltomaki P, Aaltonen LA, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993; 260: 810-812.
138. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260: 812-816.
139. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363: 558-561.
140. Halford S, Sasieni P, Rowan A, Wasan H, Bodmer W, Talbot I et al. Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. Cancer Res 2002; 62: 53-57.
141. Laiho P, Launonen V, Lahermo P, Esteller M, Guo M, Herman JG et al. Low-level microsatellite instability in most colorectal carcinomas. Cancer Res 2002; 62: 1166-1170.
142. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260: 816-819.
143. Bubb VJ, Curtis LJ, Cunnigham C, Dunlop MG, Carothers AD, Morris RG et al. Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 1996; 12: 2641-2649.
144. Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lathi M, Pylkkanen L et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993; 53: 5849-5852.
145. Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996; 110: 682-687.
146. Lukish JR, Muro K, DeNobile J, Katz R, Williams J, Cruess DF et al. Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg 1998; 227: 51-56.
147. Wright CM, Dent OF, Barker M, Newland RC, Chapuis PH, Bokey EL et al. Prognostic significance of extensive microsatellite instability in sporadic clinicipathological stage C colorectal cancer. Br J Surg 2000; 87: 1197-1202.
148. Gryfe R, Kim H, Hsieh ETK, Aronson MD, Holowaty EJ, Bull SB et al. Tumour microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342: 69-77.
149. Forster S, Sattler HP, Hack M, Romanakis K, Rohde V, Seitz G et al. Microsatellite instability in sporadic carcinomas of the proximal colon: association with diploid DNA content, negative protein expression of p53, and distinct histomorphologic features. Surgery 1998; 123: 13-18.
150. Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favourable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000; 119: 921-928.
151. Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Peterson BJ et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999; 91: 1295-1303.
152. Suh JH, Lim SD, Kim JC, Hong SH, Kang GH. Comparison of clinicopathologic characteristics and genetic alterations between microsatellite instability-positive and microsatellite instability-negative sporadic colorectal carcinomas in patients younger than 40 years old. Dis Colon Rectum 2002; 45: 219-228.
153. Samowitz WS, Curtin K, Ma KN, Schaffer D, Coleman LW, Leppert M et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 2001; 10: 917-923.
154. Colombino M, Cossu A, Manca A, Dedola MF, Giordano M, Scintu R et al. Prevalence and prognostic role of microsatellite instability in patients with rectal carcinoma. Ann Oncol 2002; 13: 1447-1453.
155. Liang JT, Chang KJ, Chen JC, Lee CC, Cheng YM, Hsu HC et al. Clinicopathologic and carcinogenetic appraisal of DNA replication error in sporadic T3 N0 M0 stage colorectal cancer after curative resection. Hepatogastroenterology 1999; 46: 883-890.
156. Feeley KM, Fullard JF, Heneghan MA, Smith T, Maher M, Murphy RP et al. Microsatellite instability in sporadic colorectal carcinoma is not an indicator of prognosis. J Pathol 1999; 188: 14-17.
157. Messerini L, Ciantelli M, Baglioni S, Palomba A, Zampi G, Papi L. Prognostic significance of microsatellite instability in sporadic mucinous colorectal cancers. Hum Pathol 1999; 30: 629-634.
158. Curran B, Lenehan K, Mulcahy H, Tighe O, Bennett MA, Kay EW et al. Replication error phenotype, clinicopathological variables and patient outcome in Dukes' B stage II (T3,N0,M0) colorectal cancer. Gut 2000; 46: 200-204.
159. Salahshor S, Kressner U, Fischer H, Lindmark G, Glimelius B, Pahlman L et al. Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor. Br J Cancer 1999; 81: 190-193.
160. Johannsdottir JT, Bergthorsson JT, Gretarsdottir S, Kristjansson AK, Ragnarsson G, Jonasson JG et al. Replication error in colorectal carcinoma; association with loss of heterozygosity at mismatch repair loci and clinicopathological variables. Anticancer Res 1999; 19: 1821-1826.
161. Ko JM, Cheung MH, Kwan MW, Wong CM, Lau KW, Tang CM et al. Genomic instability and alterations in Apc, Mcc and Dcc in Hong Kong patients with colorectal carcinoma. Int J Cancer 1999; 84: 404-409.
162. Farrington SM, McKinley AJ, Carothers AD, Cunningham C, Bubb VJ, Sharp L et al. Evidence for an age-related influence of microsatellite instability on colorectal cancer survival. Int J Cancer 2002; 98: 844-850.
163. Kruschewski M, Noske A, Haier J, Runkel N, Anagnostopoulos Y, Buhr HJ. Is reduced expression of mismatch repair genes MLH1 and MSH2 in patients with sporadic colorectal cancer related to their prognosis? Clin Exp Metastasis 2002; 19: 71-77.
164. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-5257.
165. Urosevic N, Krtolica K, Skaro Milic A, Knezevic Usag S, Duujic A. Prevalence of G-to-T transversions among K-ras oncogene mutations in human colorectal tumors in Yugoslavia. Int J Cancer 1993; 54: 249-254.
166. Minamoto T, Sawaguchi K, Mai M, Yamashita M, Sugimura T, Esumi H. Infrequent K-ras activation in superficial-type (flat) colorectal adenomas and adenocarcinomas. Cancer Res 1994; 54: 2841-2844.
167. Burmer GC, Levine DS, Kulander BG, Haggitt RC, Rubin CE, Rabinovitch PS. c Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma. Gastroenterology 1990; 99: 416-420.
168. Coles C, Thompson AM, Elder PA, Cohen BB, Mackenzie IM, Cranston G et al. Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis. Lancet 1990; 336: 761-763.
169. Jego N, Thomas G, Hamelin R. Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers. Oncogene 1993; 8: 209-213.
170. Petersen S, Thames HD, Nieder C, Petersen C, Baumann M. The results of colorectal cancer treatment by p53 status: treatment-specific overview. Dis Colon Rectum 2001; 44: 322-332.
171. Baas IO, Van Den Berg FM, Mulder JWR, Clement MJ, Slebos RJC, Hamilton SR et al. Potential false-positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. J Pathol 1996; 178: 264-267.